BMP-induced Growth Suppression in Colon Cancer Cells is Mediated by P21WAF1 Stabilization and Modulated by RAS/ERK

Overview

Journal Cell Signal

Date 2007 Feb 24

PMID 17317101

Citations 31

Authors

Stayce E Beck

Barbara H Jung

Eunice Del Rosario

Jessica Gomez

John M Carethers

Affiliations

Soon will be listed here.

Abstract

Bone morphogenetic proteins (BMPs) regulate cell differentiation, proliferation, and apoptosis through a canonical SMAD signaling cascade. Absence of BMP signaling causes the formation of intestinal juvenile polyps in the colon cancer-prone syndrome familial juvenile polyposis. As sporadic colon cancers appear to have intact BMP signaling, we evaluated if K-RAS, driving a mitogenic pathway frequently activated in colon cancer, negatively affects BMP growth suppression. We treated non-tumorigenic but activated RAS/ERK FET cells with BMP2, and in combination with pharmacological or genetic inhibition of RAS/ERK, examined BMP-SMAD signaling, transcriptional activity, and cell growth, and also assessed p21(WAF1) mRNA, transcriptional activation, and protein levels. BMP2 increased nuclear phospho-SMAD1 2-fold, which increased another 2-3 fold when RAS/ERK was inhibited. BMP2 increased BMP-specific SMAD transcriptional activity 2-fold over control and decreased cell growth, but inhibition of RAS/ERK further enhanced BMP-specific transcriptional activity by an additional 1.5-2 fold and enhanced growth suppression by 20%. BMP-induced growth suppression is mediated in part by p21(WAF1), not by transcriptional upregulation but by improved p21 protein stability, which is inhibited by RAS/ERK. In colon cancer cells, BMP-SMAD signaling and growth suppression is facilitated by p21(WAF1) but modulated by oncogenic K-RAS to reduce the growth suppression directed by this pathway.

Citing Articles

The BMP Signaling Pathway: Bridging Maternal-Fetal Crosstalk in Early Pregnancy.

Yang S, Gan J, Xu H, Shi J, Wang J, Zhang X Reprod Sci. 2025; .

PMID: 39821798 DOI: 10.1007/s43032-024-01777-4.

Insights into the Role of Gremlin-1, a Bone Morphogenic Protein Antagonist, in Cancer Initiation and Progression.

Elemam N, Imadeddin Malek A, Mahmoud E, El-Huneidi W, Talaat I Biomedicines. 2022; 10(2).

PMID: 35203511 PMC: 8869528. DOI: 10.3390/biomedicines10020301.

Aberrant expression of the extracellular matrix component Biglycan regulated by Hedgehog signalling promotes colorectal cancer cell proliferation.

Zeng S, Zhou F, Wang Y, Zhai Z, Xu L, Wang H Acta Biochim Biophys Sin (Shanghai). 2022; 54(2):243-251.

PMID: 35130618 PMC: 9909327. DOI: 10.3724/abbs.2021018.

Hyperoside suppresses BMP-7-dependent PI3K/AKT pathway in human hepatocellular carcinoma cells.

Wei S, Sun Y, Wang L, Zhang T, Hu W, Bao W Ann Transl Med. 2021; 9(15):1233.

PMID: 34532370 PMC: 8421975. DOI: 10.21037/atm-21-2980.

A four-gene signature associated with clinical features can better predict prognosis in prostate cancer.

Yuan P, Ling L, Fan Q, Gao X, Sun T, Miao J Cancer Med. 2020; 9(21):8202-8215.

PMID: 32924329 PMC: 7643642. DOI: 10.1002/cam4.3453.

References

GAYET J, Zhou X, Duval A, Rolland S, Hoang J, Cottu P . Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene. 2001; 20(36):5025-32. DOI: 10.1038/sj.onc.1204611. View

Howe J, Bair J, Sayed M, Anderson M, Mitros F, Petersen G . Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001; 28(2):184-7. DOI: 10.1038/88919. View

Grady W, Markowitz S . Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002; 3:101-28. DOI: 10.1146/annurev.genom.3.022502.103043. View

Pouliot F, Blais A, Labrie C . Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res. 2003; 63(2):277-81. View

Waite K, Eng C . BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet. 2003; 12(6):679-84. View

Gong J, Ammanamanchi S, Ko T, Brattain M . Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res. 2003; 63(12):3340-6. View

Waite K, Eng C . From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet. 2003; 4(10):763-73. DOI: 10.1038/nrg1178. View

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

Brubaker K, Corey E, Brown L, Vessella R . Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem. 2003; 91(1):151-60. DOI: 10.1002/jcb.10679. View

10.

Jung B, Doctolero R, Tajima A, Nguyen A, Keku T, Sandler R . Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology. 2004; 126(3):654-9. DOI: 10.1053/j.gastro.2004.01.008. View

11.

Wen X, Miyake S, Akiyama Y, Yuasa Y . BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun. 2004; 316(1):100-6. DOI: 10.1016/j.bbrc.2004.02.016. View

12.

Haramis A, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus G . De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science. 2004; 303(5664):1684-6. DOI: 10.1126/science.1093587. View

13.

Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M . Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. DOI: 10.1056/NEJM198809013190901. View

14.

Jung B, Smith E, Doctolero R, Gervaz P, Alonso J, Miyai K . Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer. 2005; 118(10):2509-13. PMC: 4155491. DOI: 10.1002/ijc.21710. View

15.

Beck S, Jung B, Fiorino A, Gomez J, Del Rosario E, Cabrera B . Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol. 2006; 291(1):G135-45. PMC: 4138725. DOI: 10.1152/ajpgi.00482.2005. View

16.

Morrison D, Kaplan D, Rapp U, Roberts T . Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity. Proc Natl Acad Sci U S A. 1988; 85(23):8855-9. PMC: 282605. DOI: 10.1073/pnas.85.23.8855. View

17.

Reuter C, Catling A, Jelinek T, Weber M . Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. J Biol Chem. 1995; 270(13):7644-55. DOI: 10.1074/jbc.270.13.7644. View

18.

Liu F, Ventura F, Doody J, Massague J . Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol. 1995; 15(7):3479-86. PMC: 230584. DOI: 10.1128/MCB.15.7.3479. View

19.

Blank J, Gerwins P, Elliott E, Sather S, Johnson G . Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J Biol Chem. 1996; 271(10):5361-8. DOI: 10.1074/jbc.271.10.5361. View

20.

Liu F, Hata A, Baker J, Doody J, Carcamo J, Harland R . A human Mad protein acting as a BMP-regulated transcriptional activator. Nature. 1996; 381(6583):620-3. DOI: 10.1038/381620a0. View